Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roelf Valkema

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|November 9, 2017
Prediction of long-term (> 10 year) cardiovascular outcomes in heart transplant recipients: Value of stress technetium-99m tetrofosmin myocardial perfusion imagingJesse F Veenis, Hendrik J Boiten, Jan C van den Berge, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2020
Surveillance of Clinically Complete Responders Using Serial <sup>18</sup>F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant ChemoradiotherapyMaria J Valkema, Berend J van der Wilk, Ben M Eyck, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 19, 2024
Induction chemotherapy followed by response evaluation and esophagectomy for advanced esophageal cancerCharlène J van der Zijden, Pieter C van der Sluis, Bianca Mostert, et al.
Ebiomedicine|March 22, 2024
Potential of PSMA-targeting radioligand therapy for malignant primary and secondary brain tumours using super-selective intra-arterial administration: a single centre, open label, non-randomised prospective imaging studyIlanah J Pruis, Pieter Jan van Doormaal, Rutger K Balvers, et al.
Seminars in Nuclear Medicine|April 20, 2002
Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experienceRoelf Valkema, Marion De Jong, Willem H Bakker, et al.
BMC Cancer|April 10, 2023
A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2Charlène J van der Zijden, Sjoerd M Lagarde, Merel Hermus, et al.
Nuclear Medicine Communications|May 3, 2023
External validation of 18 F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapyMaria J Valkema, Roelof J Beukinga, Avishek Chatterjee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 17, 2019
Accuracy of <sup>18</sup>F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal CancerMaria J Valkema, Bo Jan Noordman, Bas P L Wijnhoven, et al.
Haematologica|April 11, 2020
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE studyMarie José Kersten, Julia Driessen, Josée M Zijlstra, et al.
Nuclear Medicine Communications|November 20, 2023
18 F-FDG PET/MRI for restaging esophageal cancer after neoadjuvant chemoradiotherapyMaria J Valkema, Quido G de Lussanet de la Sablonière, Roelf Valkema, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|November 9, 2017
Prediction of long-term (> 10 year) cardiovascular outcomes in heart transplant recipients: Value of stress technetium-99m tetrofosmin myocardial perfusion imagingJesse F Veenis, Hendrik J Boiten, Jan C van den Berge, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2020
Surveillance of Clinically Complete Responders Using Serial <sup>18</sup>F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant ChemoradiotherapyMaria J Valkema, Berend J van der Wilk, Ben M Eyck, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 19, 2024
Induction chemotherapy followed by response evaluation and esophagectomy for advanced esophageal cancerCharlène J van der Zijden, Pieter C van der Sluis, Bianca Mostert, et al.
Ebiomedicine|March 22, 2024
Potential of PSMA-targeting radioligand therapy for malignant primary and secondary brain tumours using super-selective intra-arterial administration: a single centre, open label, non-randomised prospective imaging studyIlanah J Pruis, Pieter Jan van Doormaal, Rutger K Balvers, et al.
Seminars in Nuclear Medicine|April 20, 2002
Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experienceRoelf Valkema, Marion De Jong, Willem H Bakker, et al.
BMC Cancer|April 10, 2023
A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2Charlène J van der Zijden, Sjoerd M Lagarde, Merel Hermus, et al.
Nuclear Medicine Communications|May 3, 2023
External validation of 18 F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapyMaria J Valkema, Roelof J Beukinga, Avishek Chatterjee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 17, 2019
Accuracy of <sup>18</sup>F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal CancerMaria J Valkema, Bo Jan Noordman, Bas P L Wijnhoven, et al.
Haematologica|April 11, 2020
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE studyMarie José Kersten, Julia Driessen, Josée M Zijlstra, et al.
Nuclear Medicine Communications|November 20, 2023
18 F-FDG PET/MRI for restaging esophageal cancer after neoadjuvant chemoradiotherapyMaria J Valkema, Quido G de Lussanet de la Sablonière, Roelf Valkema, et al.
Pageof 10